SCHEMBL498074

SCHEMBL498074

COc1ccc(C2C=NNC(=O)C2)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 15/20 0.52
PDE4B Q07343 9/20 0.52
PDE4C Q08493 9/20 0.52
PDE4D Q08499 9/20 0.52
PDE3B Q13370 2/20 0.48
PDE3A Q14432 2/20 0.48
GFER P55789 1/20 0.48
KDM4E B2RXH2 2/20 0.43
POLB P06746 1/20 0.43
ESR2 Q92731 1/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GAA P10253 1/20 0.42
RAB9A P51151 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CYP3A4 P08684 2/20 0.41
VEGFA P15692 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL498001 0.88 PDE4B (0.60) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL6232341 0.87 PDE4A (0.60) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL6229342 0.87 PDE4A (0.60) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL6228237 0.87 PDE4B (0.48) PDE4APDE4BPDE4CPDE4D
SCHEMBL6229565 0.87 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL6228022 0.86 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL6232762 0.85 PDE4A (0.62) PDE4APDE4BPDE4CPDE4DHSD17B10
SCHEMBL6233638 0.85 PDE4A (0.50) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL6226932 0.85 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL6229490 0.83 PDE4A (0.49) PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-10059950-A None JP disclosed
EP-2157084-B1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE KOWA CO (JP) 2013-05-22 EP disclosed
US-8106053-B2 5-phenyl-3-pyridazinone derivative KOWA COMPANY, LTD. 2012-01-31 US disclosed
US-20100197698-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE KOWA COMPANY, LTD. (JP) 2010-08-05 US disclosed
EP-2157084-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE Kowa Company, Ltd. (JP) 2010-02-24 EP disclosed
EP-0933366-B1 5-PHENYL-3-PYRIDAZINONE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME NIKKEN CHEMICALS CO LTD (JP) 2005-04-06 EP disclosed
US-6235739-B1 ANTIINFLAMMATORY AGENTS; ANTIHISTAMINES; SKIN DISORDERS NIKKEN CHEMICALS CO., LTD. (JP) 2001-05-22 US disclosed
EP-0933366-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME Nikken Chemicals Company, Limited (JP) 1999-08-04 EP disclosed
JP-H1059950-A 5-PHNYL-3-PYRIDAZINONE DERIVATIVE NIKKEN CHEM CO LTD 1998-03-03 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197698-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE SERPINE1, MMP1, PLAT PDE4A 2167/4885PDE4B 1932/4885PDE4C 2802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.